Previous Next

ARCHIVE

№4' 2021

CARDIOLOGY

International Medical Journal, Vol. 27., Iss. 4, 2021, P. 13−17.

DOI (https://doi.org/10.37436/2308-5274-2021-4-2)

APPLICATION OF "L-BIOCOMPLEX" IN CHRONIC HEART FAILURE TREATMENT IN PATIENTS WITH METABOLIC SYNDROME

Kharkiv Medical Academy of Postgraduate Education, Ukraine

The combination of chronic heart failure and metabolic syndrome is a common clinical case. Patients with this pathology belong to the group of a high cardiovascular risk, which is explained by the higher frequency and severity of traditional cardiovascular factors. Of particular interest is the use of "L−BIOCOMPLEX (liposomal)" dietary supplement of "Biolik" company (Kharkiv, Ukraine), available in liposomal form as a set of L−carnitine + thioctic acid in cardiovascular pathology. To study its effect on treatment efficiency, 40 patients with chronic heart failure in combination with metabolic syndrome were examined. The treatment result for the patients whose complex treatment included "L−BIOCOMPLEX" at a dose of 5 ml of L−carnitine and 10 ml of thioctic acid once a day 30 minutes before meals for four weeks, and those receiving only basic therapy. It has been shown that L−BIOCOMPLEX as an additive to standard therapy improves the clinical and functional state of patients: reduces the functional class of chronic heart failure, increases exercise tolerance, enhances diastolic heart function and boosts the left ventricular ejection fraction in the left ventricle. The inclusion of "L−BIOCOMPLEX" in the traditional scheme of therapy helped to improve the quality of life of patients. As part of the combination therapy of the patients with chronic heart failure the "L−BIOCOMPLEX" positively affects lipid and carbohydrate metabolism, reduces atherogenic lipids, diminishes the severity of insulin resistance. Thus, "L−BIOCOMPLEX" has a positive influence on additional risk factors, affecting the cardiovascular prognosis and playing a significant role in the mechanisms of development and progression of heart failure.

Key words: "L−BIOCOMPLEX", L−carnitine, thioctic acid, chronic heart failure, metabolic syndrome.

REFERENCES

1. Heart failure as a newly approved diagnosis for cardiac rehabilitation: challenges and opportunities / D. E. Forman et al. // J. Am. Coll. Cardiol. 2015. № 65. R. 2652−2659.

2. Incorporating patients with chronic heart failure into outpatient cardiac rehabilitation: practical recommendations for exercise and self−care counseling−a clinical review / S. J. Keteyian, R. W. Squires, P. A. Ades, R. J. Thomas // J. Cardiopulm. Rehabil. Prev. 2014. № 34. R. 223−232. doi: https://doi.org/10.1097/hcr.0000000000000073

3. Team−Based Care for Outpatients with Heart Failure / J. W. Creaser et al. // Heart Fail. Clin. 2015. № 11. R. 379−405. doi: https://doi.org/10.1016/j.hfc.2015.03.004

4. Prevalence and Clinical Implication of Metabolic Syndrome in Chronic Heart Failure / Y. Miura et al. // Circ. J. 2010. № 9. R. 31−33.

5. Association of met− abolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey / Li Chaoyang et al. // J. Epidemiol. Community. Health. 2007. № 61. R. 67−73. doi: https://doi.org/10.1136/jech.2006.048173

6. Gromnatskiĭ N. I., Petrova G. D. Osobennosti porazheniya serdtsa pri metabolicheskom sindrome u patsientov molodogo i srednego vozrasta // Rossiĭskiĭ kardiologicheskiĭ zhurn. 2007. № 5. S. 24−27.

7. Therapeutic effects of L−carnitine and propionyl−Lcarnitine on cardiovascular diseases: a review / R. Ferrari et al. // Ann. N. Y. Acad. Sci. 2004. № 1033. R. 79−91.

8. Astashkin E. I., Glezer M. G. Role of L−carnitine in energy metabolism cardiomyocytes and treatment of diseases of cardiovascular system // Cardiol. Cardiovasc. Surg. 2012. № 6 (2). R. 58−65.

9. L−carnitine in the secondary prevention of cardiovascular disease: Systematic review and meta−analysis / J. DiNicolantonio et al. // Mayo Foundation for Medical Education and Research Mayo Clin. Proc. 2013. P. 1−8.

10. Arginine and Endothelial Function / J. Gambardella et al. // Biomedicines. 2020. № 8. R. 277. doi: 10.3390/biomedicines8080277

11. Clinical Trial about a Food Supplement Containing α−Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients / G. Derosa, A. D'Angelo, D. Romano, P. A. Maffioli // Int. J. Mol. Sci. 2016. № 17 (11). E1802. doi: https://doi.org/10.3390/ijms17111802

12. Alpha lipoic acid protects the heart againstmyocardial post ischemia−reperfusion arrhythmias via KATP channel activation in isolated rat hearts / M. Dudek et al. // Pharmacol. Rep. 2014. № 66 (3). R. 499−504. doi: https://doi.org/10.1016/j.pharep.2013.11.001

13. Advances in Integrating Traditional and Omic Biomarkers When Analyzing the Effects of the Mediterranean Diet Intervention in Cardiovascular Prevention / M. Fitó et al. // Int. J. Mol. Sci. 2016. № 17 (9). E1469. doi: https://doi.org/10.3390/ijms17091469

14. Real'naya nanofarmakologiya: 25 let razrabotki i primeneniya liposomal'nykh lekarstvennykh preparatov v Ukraine / A. S. Grigor'eva i dr. // Farmakom. 2016. № 1. S. 41−45.

15. Khromov A. S. Liposomal'nye preparaty − realizatsiya nanotekhnologii v meditsine // Farmakologіya ta lіkars'ka toksikologіya. 2016. № 2 (48). S. 14−23.

16. Svistel'nik A. V., Khanin A. L. Liposomal'nye lekarstvennye preparaty: vozmozhnosti i perspektivy // Meditsina v Kuzbase. 2014. T. 13, № 2. S. 15−17.

17. Olufadi R., Byrne C. D. Clinical and laboratory diagnosis of the metabolic syndrome // J. Clin. Pathol. 2008. № 61 (6). R. 697−706. doi: https://doi.org/10.1136/jcp.2007.048363